HUT71331A - Angiotensin ii antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy - Google Patents
Angiotensin ii antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathyInfo
- Publication number
- HUT71331A HUT71331A HU9402932A HU9402932A HUT71331A HU T71331 A HUT71331 A HU T71331A HU 9402932 A HU9402932 A HU 9402932A HU 9402932 A HU9402932 A HU 9402932A HU T71331 A HUT71331 A HU T71331A
- Authority
- HU
- Hungary
- Prior art keywords
- angiotensin
- conduction velocity
- diabetic neuropathy
- disorders associated
- impaired neuronal
- Prior art date
Links
- 229940123413 Angiotensin II antagonist Drugs 0.000 title abstract 3
- 239000002333 angiotensin II receptor antagonist Substances 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 230000001771 impaired effect Effects 0.000 title abstract 3
- 230000001537 neural effect Effects 0.000 title abstract 3
- 208000032131 Diabetic Neuropathies Diseases 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB929208116A GB9208116D0 (en) | 1992-04-13 | 1992-04-13 | Therapeutic agents |
| GB929211289A GB9211289D0 (en) | 1992-05-28 | 1992-05-28 | Heterocyclic therapeutic agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HU9402932D0 HU9402932D0 (en) | 1995-02-28 |
| HUT71331A true HUT71331A (en) | 1995-11-28 |
Family
ID=26300705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU9402932A HUT71331A (en) | 1992-04-13 | 1993-04-07 | Angiotensin ii antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy |
Country Status (14)
| Country | Link |
|---|---|
| EP (2) | EP0636027B1 (enExample) |
| JP (1) | JPH07505646A (enExample) |
| KR (1) | KR100292396B1 (enExample) |
| AT (1) | ATE181830T1 (enExample) |
| AU (1) | AU675935B2 (enExample) |
| CA (1) | CA2132544C (enExample) |
| DE (1) | DE69325574T2 (enExample) |
| DK (1) | DK0636027T3 (enExample) |
| ES (1) | ES2135472T3 (enExample) |
| GR (1) | GR3031261T3 (enExample) |
| HU (1) | HUT71331A (enExample) |
| NO (1) | NO313935B1 (enExample) |
| NZ (1) | NZ251741A (enExample) |
| WO (1) | WO1993020816A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2232663C (en) * | 1995-10-06 | 2008-04-08 | Novartis Ag | At1-receptor antagonists for preventing and treating postischemic renal failure and for protecting ischemic kidneys |
| AU1791497A (en) | 1996-02-29 | 1997-09-16 | Novartis Ag | At1 receptor antagonist for the stimulation of apoptosis |
| SK283348B6 (sk) * | 1996-04-05 | 2003-06-03 | Takeda Chemical Industries, Ltd. | Farmaceutický prípravok obsahujúci zlúčeninu s antagonickým účinkom na angiotenzín II |
| US6465502B1 (en) | 1998-12-23 | 2002-10-15 | Novartis Ag | Additional therapeutic use |
| CZ297795B6 (cs) | 1998-12-23 | 2007-03-28 | Novartis Ag | Tablety obsahující valsartan |
| CN101011390A (zh) | 1999-01-26 | 2007-08-08 | 诺瓦提斯公司 | 血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用 |
| GB0001662D0 (en) | 1999-02-06 | 2000-03-15 | Zeneca Ltd | Pharmaceutical compositions |
| US6211217B1 (en) | 1999-03-16 | 2001-04-03 | Novartis Ag | Method for reducing pericardial fibrosis and adhesion formation |
| DE10335027A1 (de) | 2003-07-31 | 2005-02-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Angiotensin II Rezeptor Antagonisten |
| EP2650011A1 (en) | 2004-12-24 | 2013-10-16 | Spinifex Pharmaceuticals Pty Ltd | Method of treatment or prophylaxis |
| US20130131007A1 (en) | 2005-09-07 | 2013-05-23 | Bebaas, Inc. | Vitamin b12 compositions |
| CN102885818B (zh) | 2006-03-20 | 2016-05-04 | 诺华股份有限公司 | 治疗或预防炎性痛的方法 |
| EP1908469A1 (en) | 2006-10-06 | 2008-04-09 | Boehringer Ingelheim Vetmedica Gmbh | Angiotensin II receptor antagonist for the treatment of systemic diseases in cats |
| CN107744519A (zh) | 2010-01-19 | 2018-03-02 | 诺华股份有限公司 | 改良神经传导速度的方法和组合物 |
| KR20250007040A (ko) | 2017-07-07 | 2025-01-13 | 베링거잉겔하임베트메디카게엠베하 | 고양이에서 전신 질환의 예방 또는 치료를 위한 안지오텐신 ii 수용체 길항제 |
| AU2024277852A1 (en) | 2023-05-24 | 2025-10-16 | Boehringer Ingelheim Vetmedica Gmbh | Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more sglt-2 inhibitors and telmisartan |
| WO2025125409A1 (en) | 2023-12-15 | 2025-06-19 | Boehringer Ingelheim Vetmedica Gmbh | Angiotensin ii receptor antagonist for the prevention of systemic diseases in cats |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ234854A (en) * | 1989-08-11 | 1993-02-25 | Ici Plc | Quinoline derivatives, preparation, intermediates and pharmaceutical compositions thereof |
| GB8927277D0 (en) * | 1989-12-01 | 1990-01-31 | Glaxo Group Ltd | Chemical compounds |
| US5140037A (en) * | 1990-03-20 | 1992-08-18 | E. I. Du Pont De Nemours And Company | Treatment of central nervous system disorders with imidazole angiotensin-ii receptor antagonists |
| US5049565A (en) * | 1990-12-07 | 1991-09-17 | Merck & Co., Inc. | Microbial transformation process for preparing anti-hypertensive products |
| GB9027211D0 (en) * | 1990-12-14 | 1991-02-06 | Smithkline Beecham Plc | Medicaments |
| GB9027210D0 (en) * | 1990-12-14 | 1991-02-06 | Smithkline Beecham Plc | Medicaments |
| AU1625192A (en) * | 1991-05-31 | 1992-12-03 | Zeneca Limited | Heterocyclic derivatives |
| EP0528762B1 (de) * | 1991-08-15 | 1997-05-07 | Novartis AG | N-Acyl-N-Heterocyclyl- oder Naphthylalkyl-Aminosäuren als Angiotensin II Antagonisten |
-
1993
- 1993-04-07 ES ES93909041T patent/ES2135472T3/es not_active Expired - Lifetime
- 1993-04-07 NZ NZ251741A patent/NZ251741A/en not_active IP Right Cessation
- 1993-04-07 HU HU9402932A patent/HUT71331A/hu not_active Application Discontinuation
- 1993-04-07 CA CA002132544A patent/CA2132544C/en not_active Expired - Fee Related
- 1993-04-07 AU AU39589/93A patent/AU675935B2/en not_active Ceased
- 1993-04-07 EP EP93909041A patent/EP0636027B1/en not_active Expired - Lifetime
- 1993-04-07 WO PCT/GB1993/000732 patent/WO1993020816A1/en not_active Ceased
- 1993-04-07 JP JP5518094A patent/JPH07505646A/ja active Pending
- 1993-04-07 EP EP98108683A patent/EP0872235A1/en not_active Withdrawn
- 1993-04-07 DE DE69325574T patent/DE69325574T2/de not_active Expired - Fee Related
- 1993-04-07 DK DK93909041T patent/DK0636027T3/da active
- 1993-04-07 AT AT93909041T patent/ATE181830T1/de not_active IP Right Cessation
-
1994
- 1994-10-11 KR KR19940703608A patent/KR100292396B1/ko not_active Expired - Fee Related
- 1994-10-12 NO NO19943846A patent/NO313935B1/no not_active IP Right Cessation
-
1999
- 1999-09-20 GR GR990402358T patent/GR3031261T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU3958993A (en) | 1993-11-18 |
| ES2135472T3 (es) | 1999-11-01 |
| ATE181830T1 (de) | 1999-07-15 |
| DE69325574T2 (de) | 2000-03-16 |
| KR100292396B1 (enExample) | 2001-09-17 |
| AU675935B2 (en) | 1997-02-27 |
| WO1993020816A1 (en) | 1993-10-28 |
| CA2132544C (en) | 2005-10-18 |
| NO943846L (no) | 1994-10-12 |
| EP0872235A1 (en) | 1998-10-21 |
| DK0636027T3 (da) | 2000-01-31 |
| NZ251741A (en) | 1997-06-24 |
| NO943846D0 (no) | 1994-10-12 |
| GR3031261T3 (en) | 1999-12-31 |
| EP0636027A1 (en) | 1995-02-01 |
| DE69325574D1 (de) | 1999-08-12 |
| CA2132544A1 (en) | 1993-10-28 |
| NO313935B1 (no) | 2002-12-30 |
| HU9402932D0 (en) | 1995-02-28 |
| JPH07505646A (ja) | 1995-06-22 |
| EP0636027B1 (en) | 1999-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUT71331A (en) | Angiotensin ii antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy | |
| SE8802570L (sv) | Ny anvaendning av 5ht-3-antagonister | |
| BE2012C005I2 (enExample) | ||
| ZA878952B (en) | Metal complex-containing pharmaceutical agents | |
| DK0411668T3 (da) | Central-cholecystokinin-antagonister til behandling af psykiatriske forstyrrelser | |
| ES2164684T3 (es) | Uso de antagonistas de taquiquininas en el tratamiento de emesis. | |
| FI972308A0 (fi) | 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi | |
| BG105256A (en) | Muscarinic agonists and antagonists | |
| FR2711140B1 (fr) | 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant. | |
| BG103968A (en) | Pharmaceutical antiviral composition containing glycirricinic acid and at least one protein with antiviral activity | |
| ES2080736T3 (es) | Uso de 2,3,4,5-tetrahidro-1h-3-benzazepinas en el tratamiento de trastornos neurologicos. | |
| IT1269185B (it) | Associazione dotata di effetto sinergico che ha un effetto antagonista dei recettori nk1 e nk2 | |
| EA200000198A1 (ru) | 2-ациламинопропанамины в качестве антагонистов рецепторов тахикининов | |
| BG101849A (en) | Bicyclic tachyquinine antagonists, their preparation and use in pharmaceutical compositions | |
| ES2150418T3 (es) | Composiciones farmaceuticas que comprenden calcitonina. | |
| MX9302142A (es) | Uso de 3r- y 3r,s-difenilmetoxi-1-(3,4-metileno-dioxifenetil)-piperidina y composicion que la contienen. | |
| GR3018795T3 (en) | Emulsion-free emulsion polymers in sustained-release pharmaceutical compositions and their production | |
| FR2656523B1 (fr) | Compositions pour l'usage cosmetique et/ou dermatologique, comprenant des pidolates metalliques. | |
| SE8802323L (sv) | 8alfa-acylaminoergolin, dess framstaellning samt farmaceutiska kompositioner innehaallande detsamma | |
| Moser | Minutes of the meeting on the time dependent mixing held at Glasgow on 10 9 92 | |
| FR2708028B1 (fr) | Dispositif pour le maintien de l'assemblage des blocs-portes, notamment lors de leur manutention, ainsi que les blocs-portes pourvus de ce dispositif. | |
| IT8919204A0 (it) | Composizione per la prevenzione e la cura di parodontopatte. | |
| IT1274012B (it) | N-acetiltriptamine-2-sostituite, antagoniste ad elevata affinita' del recettore della melatonina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC4A | Lapse of provisional application due to refusal |